Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Profit After Tax (2020 - 2025)

Lyell Immunopharma's Profit After Tax history spans 6 years, with the latest figure at -$38.8 million for Q3 2025.

  • For Q3 2025, Profit After Tax rose 12.87% year-over-year to -$38.8 million; the TTM value through Sep 2025 reached -$325.7 million, down 59.65%, while the annual FY2024 figure was -$343.0 million, 46.18% down from the prior year.
  • Profit After Tax for Q3 2025 was -$38.8 million at Lyell Immunopharma, up from -$42.7 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$8.4 million in Q4 2022 and bottomed at -$191.9 million in Q4 2024.
  • The 5-year median for Profit After Tax is -$52.9 million (2023), against an average of -$60.2 million.
  • The largest annual shift saw Profit After Tax surged 89.97% in 2022 before it crashed 530.34% in 2023.
  • A 5-year view of Profit After Tax shows it stood at -$83.7 million in 2021, then soared by 89.97% to -$8.4 million in 2022, then plummeted by 530.34% to -$52.9 million in 2023, then plummeted by 262.62% to -$191.9 million in 2024, then soared by 79.76% to -$38.8 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Profit After Tax are -$38.8 million (Q3 2025), -$42.7 million (Q2 2025), and -$52.2 million (Q1 2025).